Back to results
US 2026/0285994 A1Published application
Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome
AssigneeViela Bio, Inc.
InventorsIlias ALEVIZOS, Gabor G. ILLEI, Yan XIN, William A. REES, Donna MURRAY, Kenneth R. DER, Liangwei WANG
Life of this patent
Estimating the term…
Abstract
Provided are compositions and methods comprising a CD40L-specific Tn3 scaffold. Also provided are methods of utilizing the same for the prevention and treatment of Sjögren's syndrome.
Claims37
A method of treating Sjögren's syndrome (SS) in a subject in need thereof comprising:
- administering a Tn3 scaffold, wherein the Tn3 scaffold comprises a CD40L-specific monomer subunit, wherein the CD40L-specific monomer subunit comprises seven beta strands designated A, B, C, D, E, F, and G, and six loop regions designated AB, BC, CD, DE, EF, and FG, wherein the AB loop comprises SEQ ID NO:
- 11, the BC loop comprises SEQ ID NO:
- 12, the CD loop comprises SEQ ID NO:
- 13, the DE loop comprises SEQ ID NO:
- 14, the EF loop comprises SEQ ID NO:
- 15, and the FG loop comprises SEQ ID NO:
- 16,
- wherein the Tn3 scaffold is administered at a dose of about 1500 mg once every 4 weeks,
- wherein the subject has moderate-to-severe symptom state defined by ESSPRI score of ≥5, with a low systemic disease activity defined by ESSDAI score of <5, and wherein a Diary for Assessing Sjögren's Patient Reported Index (DASPRI) score is reduced in the subject following the administration.
6 more elements
A method of treating Sjögren's syndrome (SS) in a subject in need thereof comprising:
- administering a Tn3 scaffold, wherein the Tn3 scaffold comprises a CD40L-specific monomer subunit, wherein the CD40L-specific monomer subunit comprises seven beta strands designated A, B, C, D, E, F, and G, and six loop regions designated AB, BC, CD, DE, EF, and FG, wherein the AB loop comprises SEQ ID NO:
- 11, the BC loop comprises SEQ ID NO:
- 12, the CD loop comprises SEQ ID NO:
- 13, the DE loop comprises SEQ ID NO:
- 14, the EF loop comprises SEQ ID NO:
- 15, and the FG loop comprises SEQ ID NO:
- 16,
- wherein the Tn3 scaffold is administered at a dose of about 3000 mg once every 12 weeks,
- wherein the subject has moderate-to-severe symptom state defined by ESSPRI score≥5, with a low systemic disease activity defined by ESSDAI score<5, and wherein a Diary for Assessing Sjögren's Patient Reported Index (DASPRI) score is reduced in the subject following the administration.
6 more elements
Dependencies are inferred from the claim text.